Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials.

Abstract

Cannabidiol (CBD) is one of the cannabinoids with non-psychotropic action, extracted from Cannabis sativa. CBD is a terpenophenol and it has received a great scientific interest thanks to its medical applications. This compound showed efficacy as anti-seizure, antipsychotic, neuroprotective, antidepressant and anxiolytic. The neuroprotective activity appears linked to its excellent anti-inflammatory and antioxidant properties. The purpose of this paper is to evaluate the use of CBD, in addition to common anti-epileptic drugs, in the severe treatment-resistant epilepsy through an overview of recent literature and clinical trials aimed to study the effects of the CBD treatment in different forms of epilepsy. The results of scientific studies obtained so far the use of CBD in clinical applications could represent hope for patients who are resistant to all conventional anti-epileptic drugs.

• Authors: Serena Silvestro, Santa Mammana, Eugenio Cavalli, Placido Bramanti, Emanuela Mazzon
• Journal: Molecules (Basel, Switzerland) (Molecules) Vol. 24 Issue 8 (Apr 12 2019) ISSN: 1420-3049 [Electronic] Switzerland
• PMID: 31013866 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Anxiety Agents
• Anticonvulsants
• Antipsychotic Agents
• Cannabidiol

Topics

• Anti-Anxiety Agents (adverse effects, chemistry, therapeutic use)
• Anticonvulsants (adverse effects, chemistry, therapeutic use)
• Antipsychotic Agents (adverse effects, chemistry, therapeutic use)
• Cannabidiol (adverse effects, chemistry, therapeutic use)
• Cannabis (chemistry)
• Clinical Trials as Topic
• Epilepsy (drug therapy, pathology, physiopathology)
• Humans
• Seizures (drug therapy, pathology, physiopathology)